Clay Siegall is the CEO of Seattle Genetics. In his blog, he publishes articles on biotechnology and beyond. In an article posted on March 6, 2017, Clay gives his readers, mostly those in the Northeast, tips of what to do when bitten by a Lyme-infested tick. When bitten, one should use tweezers to carefully remove the tick without squishing it, and determine if your community has reported cases of Lyme. If Lyme is present in your region, keep the tick so that it can be tested in a lab. One should lookout for any red rash that keeps expanding. In case of these symptoms, an infected person should not hesitate to see a doctor immediately for treatment. This information was originally mentioned on NPR.
Another article on Clay’s blog says that medical breakthroughs are not always proven. More than 50 percent of published medical findings on cases like breast cancer, autism and other diseases actually work out when tested further. This blame is laid on journalists who rush to report the findings and the scientists who are overwhelmed by their findings without having clear scrutiny. This shortcoming was realized after Estelle Dumas-Mallet, a biologist, partnered with her colleagues to research on thousand journal studies. They found out that a half of those findings did not hold water when researched further. This information was originally published on NPR.
About Clay Siegall
Clay B. Siegall is the co-founder of Seattle Genetics, a biotechnology company. He also serves as the chairman of the company’s board. With extensive training in science and a deep passion for cancer therapies, Clay incorporated Seattle Genetics on a concrete foundation of scientific innovation, extensive research as well as drug development policies and the desire to help others. Today, the company is a leader in developing anti-body drug conjugates (ADC).
Previously, Clay worked for various companies, including the National Institutes of Health, Bristol-Myers Squibb Pharmaceutical Research Institute, and The National Cancer Institute. Presently, he is a member of the board of directors of Ultragenyx Pharmaceutical, Washington Roundtable and Alder BioPharmaceuticals. His outstanding performance in the field of cancer therapies has seen him win several awards, including the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year. Siegall is an alumnus of the esteemed George Washington University and the University of Maryland where he pursued genetics and zoology respectively.